Compare
Skinvisible, Inc. vs Jupiter Neurosciences, Inc. vs Bioadaptives, Inc. vs PRF Technologies Ltd.
| Latest fiscal year | Skinvisible, Inc. SKVI | Jupiter Neurosciences, Inc. JUNS | Bioadaptives, Inc. BDPT | PRF Technologies Ltd. PRFX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $20.0K | $21.8K | $18.3K | $17.0K |
| Revenue growth (YoY) | 0.0% | n/a | +44.3% | n/a |
| Gross margin | 100.0% | 80.6% | 68.4% | -311.8% (computed) |
| Operating margin | n/m | n/m | n/m | n/m |
| Net margin | n/m | n/m | n/m | n/m |
| Net income | -$1.06M | -$8.64M | -$1.56M | -$5.02M |
| EPS (Diluted) | n/a | -$0.25 | -$0.15 | -$7.47 |
| Operating cash flow | -$38.4K | -$5.41M | -$516.0K | -$3.96M |
| Free cash flow | -$42.5K | n/a | -$534.0K | -$3.96M |
| Cash & equivalents | n/a | n/a | $215.2K | $3.12M |
| Total assets | $127.6K | $5.56M | $225.9K | $12.00M |
| Total liabilities | $10.39M | $7.40M | $2.36M | $2.71M |
| Shareholders' equity | -$10.26M | -$1.83M | -$2.13M | $8.54M |
| Return on year-end equity | n/a | n/a | n/a | -58.8% |
| Shares outstanding | 5.40M | 34.45M | 12.01M | 830.6K |
Revenue, most recent five fiscal years
| Fiscal year | Skinvisible, Inc. | Jupiter Neurosciences, Inc. | Bioadaptives, Inc. | PRF Technologies Ltd. |
|---|---|---|---|---|
| Latest | $20.0K Ended 2025-12-31 | $21.8K Ended 2025-12-31 | $18.3K Ended 2025-12-31 | $17.0K Ended 2025-12-31 |
| 1 year earlier | $20.0K Ended 2024-12-31 | $0 Ended 2024-12-31 | $12.7K Ended 2024-12-31 | $0 Ended 2024-12-31 |
| 2 years earlier | $20.0K Ended 2023-12-31 | n/a | $28.6K Ended 2023-12-31 | $0 Ended 2023-12-31 |
| 3 years earlier | $279.3K Ended 2022-12-31 | n/a | $17.2K Ended 2022-12-31 | n/a |
| 4 years earlier | $663.4K Ended 2021-12-31 | n/a | $19.8K Ended 2021-12-31 | n/a |